Literature DB >> 28651928

Hypoxia-activated prodrug: an appealing preclinical concept yet lost in clinical translation.

Lars H Lindner1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28651928     DOI： 10.1016/S1470-2045(17)30401-1

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  5 in total

Review 1.  Immunotherapy on acid: opportunities and challenges.

Authors:  Sultan Damgaci; Pedro M Enriquez-Navas; Shari Pilon-Thomas; Albert Guvenis; Robert J Gillies; Arig Ibrahim-Hashim
Journal:  Eur J Clin Nutr       Date:  2020-08       Impact factor: 4.016

Review 2.  Hypoxia Imaging As a Guide for Hypoxia-Modulated and Hypoxia-Activated Therapy.

Authors:  Jeffrey R Brender; Yu Saida; Nallathamby Devasahayam; Murali C Krishna; Shun Kishimoto
Journal:  Antioxid Redox Signal       Date:  2022-01       Impact factor: 8.401

3.  Design, synthesis and biological evaluations of a long-acting, hypoxia-activated prodrug of fasudil, a ROCK inhibitor, to reduce its systemic side-effects.

Authors:  Taslim A Al-Hilal; Mohammad Anwar Hossain; Ahmed Alobaida; Farzana Alam; Ali Keshavarz; Eva Nozik-Grayck; Kurt R Stenmark; Nadezhda A German; Fakhrul Ahsan
Journal:  J Control Release       Date:  2021-04-26       Impact factor: 11.467

4.  AI-Radiomics Can Improve Inclusion Criteria and Clinical Trial Performance.

Authors:  Michal R Tomaszewski; Shuxuan Fan; Alberto Garcia; Jin Qi; Youngchul Kim; Robert A Gatenby; Matthew B Schabath; William D Tap; Denise K Reinke; Rikesh J Makanji; Damon R Reed; Robert J Gillies
Journal:  Tomography       Date:  2022-02-02

Review 5.  Hypoxia and its therapeutic possibilities in paediatric cancers.

Authors:  Carolina Bernauer; Y K Stella Man; Julia C Chisholm; Elise Y Lepicard; Simon P Robinson; Janet M Shipley
Journal:  Br J Cancer       Date:  2020-10-27       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.